Latest filing published 19 Jun 2026 for Alembic Pharma, €23k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 6 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +8.3%Entry ₹780.85 · Close at T+90 ₹845.70
- +11.0%Entry ₹748.45 · Close at T+90 ₹830.99
- +10.0%Entry ₹738.60 · Close at T+90 ₹812.15
- +12.3%Entry ₹735.70 · Close at T+90 ₹826.15
- +12.0%Entry ₹735.10 · Close at T+90 ₹823.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Nirayu Private Limited: trading record in brief
Nirayu Private Limited discloses dealings in Alembic Pharmaceuticals Limited to SEBI (PIT + SAST). We count 6 filings; the first trade dates from 25 May 2026 and the latest from 19 June 2026.
Every open-market trade on record is a purchase: 6 purchases worth €1.8M, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
In size, the median ticket on the buying side is €291k. Measured against the company's value, the median purchase equals 0.012% of market capitalisation, across 3 purchases where it is known. The 6 purchases reviewed show no overlap with other insiders buying the same stock within a month. Ninety days after publication, 6 purchases show a median change of +10.5%, with the price up in 100% of them. This is a record of the past, not a forecast.
The latest filing, published on 19 June 2026, reports an open-market purchase of €23k in Alembic Pharmaceuticals Limited. Publication is fast: at least half of the trades appear on SEBI (PIT + SAST) on the same day. Until a filing is published, the market cannot know about the trade. This summary is built from SEBI (PIT + SAST) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Nirayu Private Limited
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 3,278 shares@ ₹743.500.0016% mcap1.3% of flowEquity SharesMarket PurchaseSEBI:0f3fd4e19000e9b92f6fb742239b0fb347ecc9d0Canonical exit: 17 Sept 2026 (T+90)
- 24,832 shares@ ₹746.300.012% mcap9.6% of flowEquity SharesMarket PurchaseSEBI:635e56dbe8ddfea409988c2ae2c9b8aeb07545a1Canonical exit: 16 Sept 2026 (T+90)
- 75,000 shares@ ₹746.000.035% mcap28.6% of flowEquity SharesMarket PurchaseSEBI:fd53d3099905b66fd87728a8dd10c66ff04543cfCanonical exit: 10 Sept 2026 (T+90)
- 20,000 shares@ ₹744.007.5% of flowEquity SharesMarket PurchaseSEBI:9515f001518915fd32ca4609945968133d986788Canonical exit: 1 Sept 2026 (T+90)
- 78,000 shares@ ₹762.5030.0% of flowEquity SharesMarket PurchaseSEBI:010ada55f01065d17b85981c1127f024a82dd423Canonical exit: 26 Aug 2026 (T+90)
- 60,000 shares@ ₹758.0023.1% of flowEquity SharesMarket PurchaseSEBI:3660fa3496803de67527703cc3e8ff54a498d345Canonical exit: 23 Aug 2026 (T+90)
6 of 6 declarations